Table 2.

Chemoimmunotherapy of patients

Patient	Average number of DC administrated (106)	Average number of CIK administrated (108)	Serum CEA	Toxicity of skin (°)	Non-infective fever (°)
1	11.5 ± 1.9	18.9 ± 2.3	↑	0	I
2	6.5 ± 0.98	12.5 ± 2.5	↓	I	III
3	7.6 ± 1.7	11.3 ± 0.8	→	II	I
4	12.25 ± 2.8	11.2 ± 2.2	→	0	0
5	5.4 ± 2.5	9.9 ± 0.4	→	0	I
6	6.6 ± 0.85	19.4 ± 0.8	→	II	0
7	7.5 ± 3.3	10.8 ± 0.9	→	III	0
8	8.2 ± 0.8	16.3 ± 2.2	→	I	I
9	5.5 ± 2.5	17.7 ± 0.6	→	II	0
10	10.5 ± 0.7	13.8 ± 1.9	↓	III	II
11	8.9 ± 0.7	9.7 ± 0.4	↑	0	I
12	8.2 ± 1.0	10.4 ± 0.9	↓	I	IV
13	6.7 ± 0.9	10.9 ± 1.1	→	0	III
14	10.4 ± 2.6	11.8 ± 1.2	→	II	II

The average number of immune cells and adverse event in each patient of chemoimmunotherapy group were shown. CEA level decreased in 3 patients (21.4%), while it was stable in 9 patients (64.2%)